POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinical safety rating: safe
No significant drug interactions Can cause hypernatremia and fluid overload.
Potassium chloride provides potassium ions, which are essential for maintaining cellular membrane potential, nerve impulse conduction, and muscle contraction. Dextrose 5% provides glucose for energy, and sodium chloride 0.9% restores sodium and chloride ions, maintaining extracellular fluid volume and osmolality.
| Metabolism | Potassium is primarily excreted unchanged by the kidneys; dextrose is metabolized via glycolysis and oxidative phosphorylation; sodium and chloride are primarily renally excreted. |
| Excretion | Renal: >90% of potassium is excreted by the kidneys, primarily via distal tubular secretion and reabsorption. Fecal: <10%. Biliary: negligible. |
| Half-life | Potassium has no true elimination half-life as it is a mineral; its serum concentration is tightly regulated by renal function and cellular uptake. In anuric patients, half-life may exceed 24 hours. |
| Protein binding | Potassium is not significantly bound to plasma proteins; <5% bound. |
| Volume of Distribution | Approximately 0.2 L/kg for total body potassium; extracellular volume is ~0.05 L/kg. Represents distribution primarily in intracellular fluid (98% of body potassium). |
| Bioavailability | Intravenous: 100%. Oral: ~90% (absorbed from gastrointestinal tract). |
| Onset of Action | Intravenous: Clinical effect (serum potassium increase) begins within minutes; maximal effect in 1-2 hours. |
| Duration of Action | Intravenous: Duration of effect depends on infusion rate and renal function; typically 1-3 hours after infusion stops due to rapid redistribution and excretion. |
Adults: Intravenous infusion at a rate not exceeding 10 mEq per hour. Typical dose 10-20 mEq potassium chloride in 100-1000 mL D5 0.9% NaCl, repeated as needed based on serum potassium and clinical status.
| Dosage form | INJECTABLE |
| Renal impairment | GFR > 50 mL/min: No adjustment. GFR 30-50 mL/min: Reduce dose by 25-50% or extend interval. GFR < 30 mL/min: Contraindicated or use with extreme caution; maximum 20 mEq per 24 hours with frequent monitoring. |
| Liver impairment | No specific Child-Pugh based adjustments for potassium chloride. Use standard dosing, monitor potassium levels closely due to potential fluid and electrolyte imbalances in hepatic impairment. |
| Pediatric use | Neonates, infants, children: 0.5-1 mEq/kg per dose IV, administered at a rate not exceeding 0.5-1 mEq/kg per hour. Maximum single dose 40 mEq. Dilute in appropriate IV fluid (e.g., D5 0.9% NaCl) to a concentration not exceeding 40 mEq/L. |
| Geriatric use | Start at low end of adult dosing (e.g., 10 mEq per dose). Infuse at a reduced rate (e.g., 5 mEq per hour) to avoid hyperkalemia, particularly in patients with decreased renal function. Monitor serum potassium and renal function closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Breastfeeding | Potassium is a normal component of breast milk; potassium chloride supplementation does not significantly alter milk potassium levels. M/P ratio is not established but exogenous potassium is unlikely to affect the infant. Use is considered safe during breastfeeding. |
| Teratogenic Risk | Potassium chloride is not teratogenic in animals or humans. No fetal risks are known in any trimester when used appropriately. However, maternal electrolyte imbalances (e.g., hyperkalemia) can cause fetal arrhythmias or adverse outcomes. |
■ FDA Black Box Warning
Potassium chloride concentrate must be diluted before use. Undiluted administration can result in fatal cardiac arrhythmias. Do not administer undiluted.
| Common Effects | fluid replacement |
| Serious Effects |
["Hyperkalemia","Renal failure with oliguria or anuria","Addison's disease","Acute dehydration","Heat cramps","Concomitant use of potassium-sparing diuretics (e.g., spironolactone, amiloride, triamterene)","Severe hemolytic reactions"]
| Precautions | ["Monitor serum potassium levels closely during therapy","Risk of hyperkalemia, especially in patients with renal impairment or receiving potassium-sparing diuretics","Avoid use in patients with severe renal failure or adrenal insufficiency","Intravenous administration may cause phlebitis or extravasation","Use caution in patients with cardiac disease or conditions predisposing to hyperkalemia"] |
Loading safety data…
| Fetal Monitoring | Monitor serum potassium levels regularly during treatment. In pregnancy, monitor maternal ECG for signs of hyperkalemia or hypokalemia. Fetal heart rate monitoring may be considered if maternal electrolyte disturbances occur or if high doses are administered intravenously. |
| Fertility Effects | No known effect on fertility at therapeutic doses. Severe electrolyte imbalances may impair reproductive function indirectly. |